Recently, Perez‐Shibayama et al. [25] suggested that the BMP4–gremlin axis represents a potential therapeutic target for modulating myocardial inflammation, thereby reducing the risk of severe complications such as cardiac fibrosis and heart failure. The gene discussed is GREM1; the disease is heart failure.